AGILENT TECHNOLOGIES, INC.

Agilent Technologies, Inc. provides application-focused solutions encompassing instruments, software, consumables, and services across laboratory workflows. The company organizes its operations into three primary segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Key products include chromatography and mass spectrometry systems, cancer pathology platforms, cell analysis tools, genomic reagents, automation systems, and lab management software. It also offers contract development and manufacturing for oligonucleotide therapeutics, alongside instrument maintenance and analytical supplies. Customers encompass pharmaceutical and biopharmaceutical companies, clinical diagnostics laboratories, academic and government research organizations, and industrial testing facilities in food, chemical, environmental, and forensic sectors.

The enterprise maintains an international presence, employing approximately 18,100 people worldwide across its business units. Its primary manufacturing, research, and development activities are located in multiple United States facilities as well as sites in Australia, Canada, China, Denmark, Germany, Italy, Japan, Malaysia, the Netherlands, Singapore, and the United Kingdom. In addition, its direct service network operates across 28 countries. Incorporated in Delaware, the organization coordinates centralized fulfillment, supply chain, and global support infrastructure to serve its diverse customer accounts.

Summary of the business section of Agilent Technologies's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of October 31, 2025, we employed approximately 18,100 people worldwide.”